Get started
Author

David Christian Müller

Observed names: D.C. Müller, David C Müller, David C. Muller, David C. Müller, David Müller, Müller, David Christian
Observed institutions: University of British Columbia, University of Basel, University Hospital Bonn, University Hospital of Basel, Centre international de recherche sur le cancer, Vancouver Prostate Centre, Imperial College London
ORCID: 0000-0001-6471-6065
Observed ORCID: 0000-0001-6471-6065
OpenAlex ID: A5079515645
Circulating mitochondrial DNA in serum: A universal diagnostic biomarker for patients with urological malignancies
2010 · Jörg Ellinger, David C. Müller, et al. · Urologic Oncology Seminars and Original Investigations · 111
Prostate cancer patient‐derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens
2021 · Raphaëlle Servant, Michele Garioni, et al. · The Journal of Pathology · 83
PDF
Donor‐derived, metastatic urothelial cancer after kidney transplantation associated with a potentially oncogenic BK polyomavirus
2017 · David C Müller, Maarit Rämö, et al. · The Journal of Pathology · 47
Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma: A Step Closer to Clinical Translation?
2017 · Cyrill A. Rentsch, David C. Müller, et al. · European Urology · 46
Patterns of stemness‐associated markers in the development of castration‐resistant prostate cancer
2020 · Joël R. Federer‐Gsponer, David C. Müller, et al. · The Prostate · 24
Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance
2018 · Joël R Federer‐Gsponer, Cristina Quintavalle, et al. · The Journal of Pathology · 23
Somatic Features of Response and Relapse in Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy
2021 · Jack V.W. Bacon, David C. Müller, et al. · European Urology Oncology · 21
Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer
2019 · Sarah G. Dugas, David C. Müller, et al. · Cancer Cytopathology · 16
PDF
Sensitive Detection of Urothelial Cancer via High-volume Urine DNA Analysis
2024 · Jussi Nikkola, Lauri Ryyppö, et al. · European Urology · 14
Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flow‐sorting approach
2018 · Thomas Lorber, Noemi Andor, et al. · The Journal of Pathology · 11
ERBB2 /HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
2025 · Gillian Vandekerkhove, Andrew J. Murtha, et al. · Clinical Cancer Research · 6
Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III
2022 · M.J. Reike, M.A. Ingersoll, et al. · Urologic Oncology Seminars and Original Investigations · 6
Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer
2026 · David C. Müller, Andrew J. Murtha, et al. · Nature Communications · 5
PDF
Genomic evolutionary trajectory of metastatic squamous cell carcinoma of the lung
2021 · Arthur Krause, Luca Roma, et al. · Translational Lung Cancer Research · 5
PDF
Clonal hematopoiesis in metastatic urothelial and renal cell carcinoma
2025 · Aslı D. Munzur, Jack V. W. Bacon, et al. · npj Precision Oncology · 4
PDF
Moving Towards Minimally Invasive Genomically Based Diagnosis and Monitoring of Bladder Cancer
2016 · Cyrill A. Rentsch, David Christian Müller, et al. · European Urology · 3
Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts
2025 · Kristen D. Brantley, Michael E. Jones, et al. · Breast Cancer Research · 2
PDF
Abstract A007: Circulating tumor DNA and tissue staining analyses reveal heterogeneous ERBB2/HER2 status in urothelial cancer
2024 · Gillian Vandekerkhove, Andrew J. Murtha, et al. · Clinical Cancer Research · 1
Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer
2023 · Tatjana Vlajnic, David C. Müller, et al. · Cancer Reports · 1
PDF
Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.
2023 · Elena Schönlau, David Christian Müller, et al. · Journal of Clinical Oncology · 1
PDF
Somatic features of response and relapse in non-muscle invasive bladder cancer treated with intravesical Bacillus Calmette–Guérin
2021 · D.C. Müller, J.V.W. Bacon, et al. · European Urology · 1
Supplementary Table 13 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
2025 · Gillian Vandekerkhove, Andrew J. Murtha, et al.
Supplementary Table 10 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
2025 · Gillian Vandekerkhove, Andrew J. Murtha, et al.
Supplementary Figure 7 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
2025 · Gillian Vandekerkhove, Andrew J. Murtha, et al.
PDF
Supplementary Figure 1 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
2025 · Gillian Vandekerkhove, Andrew J. Murtha, et al.
PDF
Works count: 51
Citation count: 431
H-index: 10
I10-index: 10
Year
Topic
Type